Methylation Profiling Identifies Epigenetic Markers for High-grade Gliomas.

Hypermethylation of CpG island is an epigenetic event prevalent in human gliomas. Here we employed a high-throughput microarray approach for a global search of DNA methylation to identify novel epigenetic loci in specific glioma subtypes. Hierarchical clustering analysis separated 20 glioma samples according to their WHO histopathological subtypes - pilocytic astrocytomas (PAs, grade I), oligoastrocytomas (OAs, grade II) and glioblastomas (GBMs, grade IV), based on their unique methylation patterns. The overall methylation frequency of the low-grade PAs was significantly less than that of the more aggressive OAs and GBMs (0.45% versus 2.0% and 1.4%; PAs versus OAs, p<0.01; PAs versus GBMs, p<0.01). The lower level of DNA methylation observed in PAs may be in part due to the increased methylation of multiple CpG islands which occur in more advanced tumors. However, the young age of onset of PAs may also contribute to this observed difference. Although there were many hypermethylated loci exclusive to the OA and GBM subtypes, the methylation frequencies between these groups were not significantly different. Analysis by methylation-specific PCR on an expanded set of samples and on more glioma subtypes further confirmed an epigenetic marker, SMARCA5, the hypermethylation of which was preferentially observed in grade IV, but not in grades I or II gliomas (p<0.0001). The intermediate grade III gliomas showed low levels of SMARCA5 hypermethylation. Epigenetic loci uncovered in the present study recapitulate the histopathological differences of these gliomas, indicating that these molecular changes may be responsible for the development of the different glioma subtypes. On-going work in our laboratory has shown that some of these loci are indeed hypermethylated in the early stages of astrocytic tumors.

[1]  I. Grummt,et al.  The nucleolar remodeling complex NoRC mediates heterochromatin formation and silencing of ribosomal gene transcription , 2002, Nature Genetics.

[2]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[3]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[4]  H. Ng,et al.  Transcriptional inactivation of TP73 expression in oligodendroglial tumors , 2002, International journal of cancer.

[5]  A. Bird.  DNA methylation patterns and epigenetic memory. , 2002, Genes & development.

[6]  A. Poustka,et al.  Comprehensive Allelotype and Genetic Analysis of 466 Human Nervous System Tumors , 2000, Journal of neuropathology and experimental neurology.

[7]  T. Ono,et al.  Alteration of c‐fos gene methylation in human gliomas , 1996, Molecular carcinogenesis.

[8]  H. Yoshioka,et al.  Epigenetic silencing of PEG3 gene expression in human glioma cell lines * , 2001, Molecular carcinogenesis.

[9]  T. Huang,et al.  Methylation profiling of CpG islands in human breast cancer cells. , 1999, Human molecular genetics.

[10]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  S. Clark,et al.  High sensitivity mapping of methylated cytosines. , 1994, Nucleic acids research.

[12]  S. Baylin,et al.  Concordant methylation of the ER and N33 genes in glioblastoma multiforme , 1998, Oncogene.

[13]  C. M. Chen,et al.  Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. , 2001, Cancer research.

[14]  Yasuhiro Yonekawa,et al.  Promoter Hypermethylation of the RB1 Gene in Glioblastomas , 2001, Laboratory Investigation.

[15]  J. Costello,et al.  Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells. , 1994, The Journal of biological chemistry.

[16]  Colin C. Collins,et al.  Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors , 2002, Nature Genetics.

[17]  M. Caligiuri,et al.  Aberrant CpG-island methylation has non-random and tumour-type–specific patterns , 2000, Nature Genetics.

[18]  J. Herman,et al.  Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. , 1996, Cancer research.

[19]  T. Yoshimoto,et al.  Microsatellite instability and the PTEN1 gene mutation in a subset of early onset gliomas carrying germline mutation or promoter methylation of the hMLH1 gene , 2000, Oncogene.

[20]  Webster K. Cavenee,et al.  The WHO Classification of Tumors of the Nervous System , 2002 .

[21]  M. Wolter,et al.  Oligodendroglial Tumors Frequently Demonstrate Hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) Tumor Suppressor Genes , 2001, Journal of neuropathology and experimental neurology.

[22]  M. Berger,et al.  Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. , 1996, Cancer research.

[23]  N. Ahuja,et al.  Methylation and silencing of the Thrombospondin-1 promoter in human cancer , 1999, Oncogene.

[24]  S. Baylin,et al.  p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3 , 1995, Nature Genetics.